FDA Clears Delphinus’s Breast Ultrasound Tomography System
Delphinus Medical Technologies Inc., a Michigan-based ultrasound company, has received FDA 510(k) clearance for its whole breast ultrasound tomography system for diagnostic breast imaging.
The SoftVue system uses ring transducer technology to transmit and receive ultrasound signals. Traditional hand-held ultrasound and automated breast ultrasound systems obtain reflected echoes returning in the direction of the linear transducer, where this system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast, according to the company. There is currently no other ultrasound system available that does that, the company said.
The breast is suspended in warm water, and the exams are one to two minutes per breast, the company said. SoftVue provides a complete map of the whole breast, and the exam is more consistent and uniform than traditional ultrasound, according to the company.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
